Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.RaQualia Pharma, engaged in the discovery, development and marketing of clinical and pre-clinical drug candidates, has entered into a licensing deal with CJ CheilJedang.
Subscribe to our email newsletter
Under the contract, RaQualia has licensed the development, manufacturing and commercialization rights of 5-HT4 Partial Agonist (RQ-00000010) to CJ in India, Taiwan, Korea and South Asia.
As per the terms of the agreement, CJ is responsible to pay an upfront payment to RaQualia.
Additionally, CJ will also pay development milestones and royalties on sales of products commercialized under the license to RaQualia.